- cafead Oct 16, 2023 at 11:43: PM
via Five months after its acquisition of Atea Pharmaceuticals fell through, Concentra Biosciences has set its sights on another struggling biotech: Rain Oncology.
Rain has had a rough time of it recently, with the company laying off 65% of its workforce at the end of May in the wake of the failure of its lead asset milademetan in a phase 3 trial for liposarcoma. Rain also said it would halt other trials of the MDM2 inhibitor and explore options that could “enhance” its pipeline through a precision oncology acquisition.
article source
Rain has had a rough time of it recently, with the company laying off 65% of its workforce at the end of May in the wake of the failure of its lead asset milademetan in a phase 3 trial for liposarcoma. Rain also said it would halt other trials of the MDM2 inhibitor and explore options that could “enhance” its pipeline through a precision oncology acquisition.
article source